![Wolf-Hagen Schunck](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Wolf-Hagen Schunck active positions
Companies | Position | Start | End |
---|---|---|---|
OMEICOS Therapeutics GmbH
![]() OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Director/Board Member | 31/12/2012 | - |
Founder | 31/12/2012 | - |
Career history of Wolf-Hagen Schunck
Statistics
International
Germany | 2 |
Operational
Director/Board Member | 1 |
Founder | 1 |
Sectoral
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
OMEICOS Therapeutics GmbH
![]() OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Health Technology |
- Stock Market
- Insiders
- Wolf-Hagen Schunck
- Experience